Novo Nordisk A/S (NVO.N)
|Market Cap (Mil.):||$73,995.22|
|Shares Outstanding (Mil.):||442.51|
COPENHAGEN - Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential.
COPENHAGEN, May 24 - Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential.
COPENHAGEN, May 24 - Denmark's Novo Nordisk said it expects to launch its liraglutide obesity treatment in the Unites States at the end of next year or start of 2015 after Phase III results late on Thursday confirmed weight loss in patients.
COPENHAGEN - Denmark's Novo Nordisk, the world's biggest insulin producer, said Phase III study results had shown people treated with its liraglutide drug had an 8 percent weight loss.
STOCKHOLM, May 23 - Novo Nordisk A/S : * Novo Nordisk A/S : Novo Nordisk reports 8% weight loss in phase 3a obesity
COPENHAGEN - Denmark's Novo Nordisk, the world's biggest insulin producer, said on Friday it had completed the first phase III trial of a hemophilia drug, N9-GP.
(Adds Sanoma, Volvo, updates A.P. Moller-Maersk, FLSmidth)
NEW YORK - Europe must start paying more for new medicines and take some of the cost burden of supporting pharmaceutical drug development off the United States, Novo Nordisk's Chief Executive Lars Sorensen said.
NEW YORK - Novo Nordisk's long-term profit targets are hanging in the balance after a big setback in the U.S. market but the Danish drugmaker may yet hit its goal if things work out for one of two drugs, its CEO said.
PARIS, May 2 - Sanofi is stepping up the development of a fixed combination of diabetes treatments Lantus and Lyxumia to sidestep an earlier setback with a similar pen device and take advantage of the delayed U.S. launch of competitor Novo Nordisk's new insulin.